XETRA - Delayed Quote EUR

Merck & Co., Inc. (6MK.DE)

97.70

+0.50

+(0.51%)

At close: January 10 at 5:35:38 PM GMT+1

Cramer on Merck & Co. (MRK): Trading Like a Value Trap Despite Strong Fundamentals

We recently published a list of Jim Cramer Discussed These 29 Stocks Ahead Of Major AI Event. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks ahead of major AI event that Jim Cramer discussed. In his appearance on Squawk on the Street […]

Insider Monkey yesterday

MRK
Medicare drug prices nearly double, surpassing inflation: AARP

A new report from AARP Public Policy Institute found that the top 25 drugs prescribed under Medicare Part D have nearly doubled in price since market entry, exceeding inflation trends. Yahoo Finance senior health reporter Anjalee Khemlani joins Brad Smith on Wealth to discuss the findings, highlighting significant cost increases for key medications, including Merck's (MRK) diabetes drug Janumet, soaring nearly 300% in its lifetime on the market dating back to 2007. While Medicare is beginning to negotiate prices, GLP-1 weight-loss drugs like Novo Nordisk's (NVO) Ozempic are already seeing price increases since their debuts. To watch more expert insights and analysis on the latest market action, check out more Wealth! here. This post was written by Josh Lynch

Yahoo Finance Video yesterday

MRK
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

Investor's Business Daily 2 days ago

AMGN

LLY

PFE
Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Simply Wall St. 3 days ago

MRK
Merck’s GARDASIL® Receives Expanded Approval for Males in China

RAHWAY, N.J., January 08, 2025--Merck’s GARDASIL® Receives Expanded Approval for Males in China

Business Wire 3 days ago

MRK
WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global uncertainties.

The Wall Street Journal 4 days ago

MRK
Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

RAHWAY, N.J., January 06, 2025--Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire 5 days ago

MRK
UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH). Sotatercept is used, in combination with other medicines, to treat PAH in adults with moderate or marked physical activity limitations and improve exercise capacity. The recommended dosing schedule is one injection every three weeks via self-administration. Also Read: Big Biopharma Trails Behind The Market

Benzinga 9 days ago

MRK
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

Zacks 9 days ago

MRK
The 5 worst-performing stocks on the Dow Jones Industrial Average in 2024

The Dow's biggest losers include companies in the aerospace, biopharma, and sports apparel sectors.

TheStreet 10 days ago

^DJI

JNJ

BA
Is Merck & Co., Inc. (MRK) Among the Best Low Volatility Stocks to Buy Right Now?

We recently published a list of 8 Best Low Volatility Stocks To Buy Right Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best low volatility stocks to buy right now. The market has shown strong performance overall, with the S&P 500 up […]

Insider Monkey 11 days ago

MRK
Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 79%

Key Insights Given the large stake in the stock by institutions, Merck's stock price might be vulnerable to their...

Simply Wall St. 11 days ago

MRK
Is Merck & Co., Inc. (MRK) the Best Pharma Dividend Stock to Buy In 2024?

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 […]

Insider Monkey 12 days ago

MRK
Merck & Co. Inc. (MRK): Billionaire D.E. Shaw Is Bullish On This Stock Right Now

We recently compiled a list of the 10 Best Stocks to Buy According to Billionaire D.E. Shaw. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against the other stocks. Equity market pricing is never perfect due to supply and demand imbalances, emotional reactions, and errors. Billionaire […]

Insider Monkey 15 days ago

MRK
Will Weakness in Merck & Co., Inc.'s (NYSE:MRK) Stock Prove Temporary Given Strong Fundamentals?

With its stock down 12% over the past three months, it is easy to disregard Merck (NYSE:MRK). But if you pay close...

Simply Wall St. 15 days ago

MRK
3 biggest catalysts expected for healthcare in 2025

After an eventful year in the pharmaceutical and biotech industries, what lies ahead for the health landscape in 2025? Yahoo Finance senior health reporter Anjalee Khemlani outlines the three biggest catalysts for change and innovation for healthcare in the new year, including GLP-1 weight-loss drugs and proposed regulations on pharmacy benefit managers (PBMs) from the second Trump administration. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 18 days ago

NONOF

NVO

LLY
Discover US Dividend Stocks For December 2024

As the U.S. stock market navigates through a mixed December, with encouraging inflation data providing some relief amidst recent declines, investors are keenly observing opportunities that can offer stability and income. In this context, dividend stocks stand out as attractive options for those seeking consistent returns in a volatile environment, offering potential benefits such as regular income and reduced portfolio volatility.

Simply Wall St. 19 days ago

ITRN

MRK

BG
Personalis price target raised to $8 from $7 at BTIG

BTIG raised the firm’s price target on Personalis (PSNL) to $8 from $7 and keeps a Buy rating on the shares. The company’s $50M investment from Merck (MRK) strengthens its balance sheet with another strategic partner and represents a major derisking event, the analyst tells investors in a research note. The firm also cites Personalis having extended their contract with Moderna (MRNA), which is now a 10-year contact and has two 5-year renewable options, adding that despite the higher move in the

TipRanks 21 days ago

MRNA

PSNL

MRK
Merck closes exclusive global license agreement for LM-299 from LaNova Medicines

Merck (MRK) announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, from LaNova Medicines. As previously announced, Merck will develop, manufacture and commercialize LM-299. Merck will record a pre-tax charge relating to the upfront payment of $588M, or approximately 18c per share, in the company’s fourth quarter 2024 GAAP and non-GAAP results. LaNova is also eligible to receive up to $2.7B in milestone payments associate

TipRanks 21 days ago

MRK
BMO cuts rating on Merck and Biogen, on lack of near term catalyst

Investing.com -- BMO Capital Markets downgraded Merck &Company Inc (NYSE:MRK) to "market perform" from "outperform," citing concerns over its Gardasil franchise in China and uncertainty around filling the revenue gap as Keytruda faces loss of exclusivity and biosimilar competition.

Investing.com 22 days ago

BIIB

MRK

Performance Overview

Return	6MK.DE	S&P 500
YTD	+2.41%	-1.35%
1-Year	-7.55%	+22.51%
3-Year	+52.49%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Merck & Co., Inc. (6MK.DE)

Cramer on Merck & Co. (MRK): Trading Like a Value Trap Despite Strong Fundamentals

Medicare drug prices nearly double, surpassing inflation: AARP

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet

Merck’s GARDASIL® Receives Expanded Approval for Males in China

WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million

Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

The 5 worst-performing stocks on the Dow Jones Industrial Average in 2024

Is Merck & Co., Inc. (MRK) Among the Best Low Volatility Stocks to Buy Right Now?

Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 79%

Is Merck & Co., Inc. (MRK) the Best Pharma Dividend Stock to Buy In 2024?

Merck & Co. Inc. (MRK): Billionaire D.E. Shaw Is Bullish On This Stock Right Now

Will Weakness in Merck & Co., Inc.'s (NYSE:MRK) Stock Prove Temporary Given Strong Fundamentals?

3 biggest catalysts expected for healthcare in 2025

Discover US Dividend Stocks For December 2024

Personalis price target raised to $8 from $7 at BTIG

Merck closes exclusive global license agreement for LM-299 from LaNova Medicines

BMO cuts rating on Merck and Biogen, on lack of near term catalyst

Performance Overview